Data / Drug companies / Neomycin sulfate, polymyxin b sulfate and dexamethasone
Neomycin sulfate, polymyxin b sulfate and dexamethasone: 11 companies and 12 products in the FDA NDC directory
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Neomycin sulfate, polymyxin b sulfate and dexamethasone is listed in the FDA National Drug Code Directory by 11 companies, with 12 products in commercial distribution. 8 of the products (66.7%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are suspension/ drops; suspension; ointment, and the newest product started marketing on March 31, 2025.
The request: Get every company that lists neomycin sulfate, polymyxin b sulfate and dexamethasone in the FDA NDC directory, with headquarters, website and number of employees. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 11
- Products
- 12
- Generic (ANDA) products
- 8 (66.7%)
- Application numbers
- 4
- Routes
- Ophthalmic
- Brand names
- Neomycin Polymyxin B Sulfates and Dexamethasone, Maxitrol, Neomycin and Polymyxin B Sulfates and Dexamethasone, Maxitrol
- openFDA record search
- api.fda.gov
Companies that list neomycin sulfate, polymyxin b sulfate and dexamethasone
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| NuCare Pharmaceuticals,Inc. | 2 | suspension/ drops; suspension | Generic drugs (ANDA) | February 21, 1996 |
| A-S Medication Solutions | 1 | suspension/ drops | Generic drugs (ANDA) | September 13, 1995 |
| Bausch & Lomb Incorporated | 1 | suspension/ drops | Generic drugs (ANDA) | September 13, 1995 |
| Harrow Eye, LLC | 1 | suspension | New drug applications (NDA) | November 15, 1964 |
| Nordic Pharma, Inc. | 1 | suspension | Authorized generics (NDA) | March 31, 2025 |
| Novartis Pharmaceuticals Corporation | 1 | ointment | New drug applications (NDA) | January 17, 1972 |
| Preferred Pharmaceuticals Inc. | 1 | suspension/ drops | Generic drugs (ANDA) | March 14, 2013 |
| Proficient Rx LP | 1 | suspension/ drops | Generic drugs (ANDA) | September 13, 1995 |
| Sandoz Inc | 1 | suspension | Generic drugs (ANDA) | February 21, 1996 |
| Sandoz Inc | 1 | ointment | New drug applications (NDA) | January 17, 1972 |
| Sportpharm LLC | 1 | suspension/ drops | Generic drugs (ANDA) | September 13, 1995 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Suspension/ drops | 6 | 50% |
| Suspension | 4 | 33.3% |
| Ointment | 2 | 16.7% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 8 | 66.7% |
| New drug applications (NDA) | 3 | 25% |
| Authorized generics (NDA) | 1 | 8.3% |
Pharmacologic classes
| Class | Products |
|---|---|
| Aminoglycoside Antibacterial | 12 |
| Corticosteroid | 12 |
| Polymyxin-class Antibacterial | 12 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.